| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d5079c4242bfd5be471374b79ddcac22 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61N2005-109
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61N2005-1098 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61N5-1077
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K41-0095
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-64 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-64
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-08 |
| filingDate |
2019-06-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fefbdb5a59fafa30c90286ce6228b5f1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cd84f75190056855148b0b3dddcc98af
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cae1f3b7451fd36b4e11293d9e9edeef
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_26f5eb49400c245cb7a420619e70e44a |
| publicationDate |
2021-04-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-3811980-A1 |
| titleOfInvention |
Accumulative boron 10 medicine for boron neutron capture therapy for selectively or locally targeting tumor tissues in short time |
| abstract |
The purpose of the present invention is to provide a 10 B medicine that can be selectively accumulated in tumor tissues at a low dose in a short time, and can be applied to BNCT. The 10 B medicine comprises a compound containing: a peptide capable of selectively binding to tumor vascular endothelial cells; and 10 B, wherein the 10 B medicine is administered to a subject suffering from cancer at a dose of 300-600mg per administration, and is accumulated after the administration such that the concentration of 10 B in the cancer tissue of the subject becomes 1ppm or higher. |
| priorityDate |
2018-06-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |